LivaNova (NASDAQ:LIVN) Sets New 1-Year High – Time to Buy?

LivaNova PLC (NASDAQ:LIVN) hit a new 52-week high on Wednesday . The stock traded as high as $74.32 and last traded at $72.8950, with a volume of 801796 shares changing hands. The stock had previously closed at $72.23.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on LIVN shares. Stifel Nicolaus set a $80.00 price objective on LivaNova in a report on Wednesday, February 25th. Needham & Company LLC lifted their price objective on LivaNova from $64.00 to $81.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Barclays lifted their price objective on LivaNova from $73.00 to $76.00 and gave the company an “equal weight” rating in a report on Thursday, May 7th. Robert W. Baird dropped their price objective on LivaNova from $78.00 to $76.00 and set an “outperform” rating for the company in a report on Thursday, May 7th. Finally, Mizuho lifted their price objective on LivaNova from $85.00 to $90.00 and gave the company an “outperform” rating in a report on Thursday, May 7th. Six equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $79.38.

LivaNova Stock Performance

The company has a 50 day moving average price of $65.04 and a 200-day moving average price of $63.42. The company has a current ratio of 1.33, a quick ratio of 1.11 and a debt-to-equity ratio of 0.24. The company has a market cap of $4.05 billion, a P/E ratio of 37.76 and a beta of 0.82.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings results on Wednesday, May 6th. The company reported $0.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.13. LivaNova had a return on equity of 16.48% and a net margin of 7.48%.The company had revenue of $362.26 million for the quarter, compared to analyst estimates of $346.05 million. During the same quarter last year, the company posted $0.88 EPS. The company’s revenue for the quarter was up 14.3% compared to the same quarter last year. LivaNova has set its FY 2026 guidance at 4.200-4.300 EPS. On average, equities analysts expect that LivaNova PLC will post 3.72 earnings per share for the current fiscal year.

Hedge Funds Weigh In On LivaNova

Several hedge funds and other institutional investors have recently modified their holdings of LIVN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of LivaNova by 4.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 35,497 shares of the company’s stock valued at $1,394,000 after purchasing an additional 1,360 shares during the last quarter. Goldman Sachs Group Inc. increased its stake in shares of LivaNova by 4.6% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,974 shares of the company’s stock valued at $32,012,000 after purchasing an additional 36,094 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of LivaNova by 10.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 168,863 shares of the company’s stock valued at $6,633,000 after purchasing an additional 15,405 shares during the last quarter. Intech Investment Management LLC increased its stake in shares of LivaNova by 19.6% in the 1st quarter. Intech Investment Management LLC now owns 43,879 shares of the company’s stock valued at $1,724,000 after purchasing an additional 7,195 shares during the last quarter. Finally, Strs Ohio bought a new position in shares of LivaNova in the 1st quarter valued at $130,000. Institutional investors own 97.64% of the company’s stock.

LivaNova Company Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.